Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes

Figures & data

Table 1. Baseline characteristics of study population (N = 104).

Characteristics
Age at vaccination (years)
Mean (SD)	58.2 (4.8)
Median	57.8
Minimum - Maximum	50.1 – 71.9
Gender
Female n (%)	59 (56.7%)
Male n (%)	45 (43.3%)
Body Mass Index (kg/m^2)
Mean (SD)	27.0 (4.0)
Median	26.7
Minimum - Maximum	19.7 – 38.9

Table 2. Antibody concentration (µg/mL) for pneumococcal serotypes 10A, 11A, 15B and 17F as measured by ELISA.

Parameter	Pneumococcal Serotype
	10A		11A		15B		17F
	Baseline	Post-vaccination^*	Baseline	Post-vaccination	Baseline	Post-vaccination	Baseline	Post-vaccination
Geometric Mean Concentration (µg/mL)	0.7	6.5	1.0	4.3	1.8	14.7	0.4	5.1
95% Confidence Interval (CI)	0.6, 1.0	4.9, 8.7	0.8, 1.2	3.6, 5.1	1.4, 2.3	11.9, 18.3	0.3, 0.6	3.9, 6.5
Median	0.7	6.7	1.0	4.5	1.9	14.1	0.4	5.1
Mean GMC Fold-rise	9.0		4.5		8.4		11.5
95% CI	7.2, 11.2		3.8, 5.4		6.8, 10.3		8.9, 14.9
Median	9.9		4.0		9.1		12.3
Proportion of Subjects with ≥2 -fold rise from baseline (Mean)	90.4%		84.6%		88.5%		89.4%
95% CI	83.0, 95.3		76.2, 90.9		80.7, 93.9		81.9, 94.6

* Post-vaccination refers to 1 month (i.e., 21 to 35 d) following vaccination with PPV23

Figure 1. Serotype-specific IgG GMC Reverse Cumulative Distribution Curves at baseline and 30 d post-vaccination.